Mizuho Securities USA LLC Buys 92,895 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Mizuho Securities USA LLC lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 2,336.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,871 shares of the medical research company's stock after buying an additional 92,895 shares during the quarter. Mizuho Securities USA LLC owned 0.19% of Charles River Laboratories International worth $19,081,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in CRL. Empirical Finance LLC lifted its holdings in Charles River Laboratories International by 4.2% in the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock valued at $258,000 after purchasing an additional 53 shares in the last quarter. CIBC Asset Management Inc increased its position in Charles River Laboratories International by 8.6% during the 3rd quarter. CIBC Asset Management Inc now owns 7,531 shares of the medical research company's stock worth $1,483,000 after purchasing an additional 595 shares in the last quarter. Zions Bancorporation N.A. lifted its position in Charles River Laboratories International by 17.6% during the third quarter. Zions Bancorporation N.A. now owns 8,527 shares of the medical research company's stock valued at $1,680,000 after buying an additional 1,275 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in Charles River Laboratories International by 3.4% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock worth $22,060,000 after buying an additional 3,714 shares during the period. Finally, Baillie Gifford & Co. raised its stake in shares of Charles River Laboratories International by 1.6% in the 3rd quarter. Baillie Gifford & Co. now owns 68,585 shares of the medical research company's stock valued at $13,509,000 after acquiring an additional 1,048 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

Shares of CRL stock traded down $9.16 during mid-day trading on Friday, reaching $187.74. The stock had a trading volume of 1,499,025 shares, compared to its average volume of 624,577. The firm has a market cap of $9.60 billion, a PE ratio of 23.50, a P/E/G ratio of 5.33 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a one year low of $176.48 and a one year high of $275.00. The firm's 50 day simple moving average is $195.26 and its 200 day simple moving average is $207.52.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. During the same quarter last year, the company earned $2.72 earnings per share. The company's revenue for the quarter was down 1.6% compared to the same quarter last year. On average, analysts forecast that Charles River Laboratories International, Inc. will post 10.19 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, August 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 9.6% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Barclays decreased their target price on Charles River Laboratories International from $230.00 to $210.00 and set an "equal weight" rating for the company in a research report on Thursday, August 8th. Bank of America lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $250.00 to $215.00 in a research report on Wednesday, October 2nd. Baird R W lowered Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 8th. Citigroup cut shares of Charles River Laboratories International from a "neutral" rating to a "sell" rating and decreased their price objective for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. Finally, TD Cowen increased their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research note on Monday, November 11th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus price target of $217.54.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).